K. Altundag And M. Z. Baptista, "Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer," BREAST JOURNAL , vol.12, no.5, pp.497-498, 2006
Altundag, K. And Baptista, M. Z. 2006. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer. BREAST JOURNAL , vol.12, no.5 , 497-498.
Altundag, K., & Baptista, M. Z., (2006). Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer. BREAST JOURNAL , vol.12, no.5, 497-498.
Altundag, Kadri, And Mauricio Z. Baptista. "Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer," BREAST JOURNAL , vol.12, no.5, 497-498, 2006
Altundag, Kadri And Baptista, Mauricio Z. . "Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer." BREAST JOURNAL , vol.12, no.5, pp.497-498, 2006
Altundag, K. And Baptista, M. Z. (2006) . "Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer." BREAST JOURNAL , vol.12, no.5, pp.497-498.
@article{article, author={Kadri Altundag And author={Mauricio Z. Baptista}, title={Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer}, journal={BREAST JOURNAL}, year=2006, pages={497-498} }